Optimer Pharmaceuticals



		Subscribe to RSS feed 2010 \| 2009 \| 2008 \| 2007 \| 2006 \| 2005 \| 2004 \| 2002 \| 2001 \| (12.16.2009) SAN DIEGO, CA Optimer Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference (12.3.2009) SAN DIEGO, CA Optimer Pharmaceuticals Appoints Robert L. Zerbe, M.D. to its Board of Directors (11.24.2009) SAN DIEGO Optimer Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference (11.12.2009) SAN DIEGO Optimer Pharmaceuticals Completes Enrollment in Second Fidaxomicin Phase 3 Clinical Trial in Patients with Clostridium difficile Infection (11.3.2009) SAN DIEGO, CA Optimer Pharmaceuticals Reports Third Quarter 2009 Financial Results (10.31.2009) SAN DIEGO Additional Data from Fidaxomicins Phase 3 Study for Clostridium difficile infection (CDI) Presented at IDSA Annual Meeting (10.26.2009) SAN DIEGO, CA Optimer Pharmaceuticals to Present at November 2009 Investor Conferences (10.19.2009) SAN DIEGO Optimer Pharmaceuticals Announces Presentations of Additional Data from the Fidaxomicin North American Phase 3 Trial at Upcoming IDSA Annual Meeting (9.28.2009) SAN DIEGO Optimer Pharmaceuticals to Present at October 2009 Investor Conferences (9.16.2009) SAN FRANCISCO VIDEO Medical News from ICAAC: InFocus on Hospital-Related Infection Control (9.15.2009) SAN DIEGO Optimer Announces Presentation of Additional Data from Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection (CDI) (9.14.2009) SAN DIEGO Data from Optimers Second Phase 3 Study of Prulifloxacin Presented at Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) (9.3.2009) SAN DIEGO Optimer Pharmaceuticals to Present at September 2009 Investor Conferences (9.2.2009) SAN DIEGO Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting (8.5.2009) SAN DIEGO Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results (8.4.2009) SAN DIEGO Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference (6.4.2009) SAN DIEGO Optimer Pharmaceuticals to Present at June 2009 Investor Conferences (6.2.2009) SAN DIEGO Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin versus Vancocin in Subgroup Analyses from its Phase 3 Study for the Treatment of CDI (5.17.2009) SAN DIEGO, CA Optimer Pharmaceuticals Presents Results from Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection (5.7.2009) SAN DIEGO Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results (4.13.2009) SAN DIEGO Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin (3.11.2009) SAN DIEGO Optimer Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Financial Results (3.9.2009) SAN DIEGO Optimer Pharmaceuticals to Present at the Cowen and Company 29th Annual Health Care Conference (3.5.2009) SAN DIEGO Optimer Pharmaceuticals to Raise $32.9 Million in Registered Direct Offering (3.3.2009) SAN DIEGO Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2008 Financial Results (3.2.2009) SAN DIEGO Optimer Pharmaceuticals to Accelerate European Filing of Fidaxomicin (OPT-80) (2.24.2009) SAN DIEGO Optimer Pharmaceuticals Announces Positive Results from Second Phase 3 Study of Prulifloxacin for Infectious Diarrhea in Travelers (2.23.2009) SAN DIEGO, CA Optimer Pharmaceuticals Appoints Industry Veterans Francois-Xavier Frapaise as Chief Scientific Officer and Peter E. Grebow to its Board of Directors

(3.3.2010) SAN DIEGO, CA

Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2009 Financial Results

SAN DIEGO, Calif. – March 3, 2010 - Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced it expects to report fourth quarter and full year 2009 financial results after the NASDAQ Global Market closes on Thursday, March 11, 2010. The Company also expects to host a conference call that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results and highlights for the fourth quarter and full year 2009, as well as provide a corporate update.

The conference call may be accessed by dialing (877) 375-5161 for domestic callers and (631) 291-4558 for international callers. Please specify to the operator that you would like to join “Optimer’s Earnings Call.” The conference call will be webcast live under the Investors section of Optimer’s website at www.optimerpharma.com, where it will be archived for 30 days following the call. Please connect to Optimer’s website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Optimer Pharmaceuticals

Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative anti-infectives to treat serious infections and address unmet medical needs. Optimer has two late-stage anti-infective product candidates under development. Fidaxomicin, formerly known as OPT-80, is a new class of antibiotics with narrow spectrum bactericidal activity targeted at the site of infection. Recently reported positive top-line results from the second Phase 3 trial confirmed the results from the first Phase 3 trial regarding fidaxomicin’s safety and efficacy in patients with Clostridium difficile infection. Optimer has also successfully completed two Phase 3 trials with Pruvel™, for the treatment of travelers’ diarrhea, a form of infectious diarrhea. Additional information can be found at http://www.optimerpharma.com.

Contacts

Optimer Pharmaceuticals, Inc.

John Prunty, CFO & VP, Finance

Christina Donaghy, Corporate Communications Manager

858-909-0736

Porter Novelli Life Sciences

Jason I. Spark, Vice President

619-849-6005